Life after Lonza: Sartorius looks to build inhouse culture media biz

Dan Stanton, Managing editor

January 30, 2019

2 Min Read
Life after Lonza: Sartorius looks to build inhouse culture media biz
Lonza and Sartorius ended their exclusive cell culture media partnership in November 2018

After a six-year partnership with CDMO Lonza ended, Sartorius Stedim Biotech says it is looking to build its own cell culture media business.

In November 2018, bioprocessing vendor Sartorius and contract development and manufacturing organization (CDMO) Lonza ended a supply and distribution partnership forged in December 2012 for media and buffers used in the manufacture of protein-based therapeutics and vaccines.

Under terms of the deal, Lonza manufactured the media and Sartorius had the exclusive sales and marketing rights. Customers of both companies are still able to source media products under a now non-exclusive supply deal, but Sartorius said this week it intends to develop its own cell culture media business.


Lonza and Sartorius ended their exclusive cell culture media partnership in November 2018

Sales figures for cell culture media have not historically been divulged, but CEO Joachim Kreuzburg said that “after having shown that we are absolutely able to grow such a business and to triple it within three years,” it is an area which Sartorius wishes to continue.

“Therefore, we are working on potential ways to build up a more or less fully-owned sales culture media business within our portfolio,” he continued, though added ensuring quality and sustainability is a priority over speed-to-market.

“We still have access to sales culture media from Lonza so we are able to serve our customers. There is no rush that we are in here, but I could definitely imagine that in the long or mid-term we will build up one way or other in [our] sales culture media business.”

According to an investor presentation from September 2018, Sartorius trail behind Thermo Fisher, (Merck) MilliporeSigma, and GE Healthcare in the cell culture media space.


The end of the Lonza deal will see Sartorius take a €40 million ($45 million) hit on its Bioprocess Solutions Division 2019 forecast, though the business will continue to grow.

“We expect a top line growth of between 8% to 12%. Here, we have factored in a dilution of around three percentage points presumably following the modification of the agreement with Lonza regarding cell culture media,” Kreuzburg told stakeholders.

For 2018, the Bioprocess Solutions Division reported another year of double-digit growth, up 14.8% to €1.14 billion. Meanwhile, order intake increased 14.9% year-on-year to €1.23 billion, driven by equipment and Sartorius’ single-use product portfolio.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like